Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review.
Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR) mutation. As a consequence, targeted therapy based on screening of tyrosine-kinase inhibitors (TKIs) is necessary. Spinal cord metastasis of lung cancer is a serious clinical problem. Here, we report a case of lung adenocarcinoma with severe spinal cord metastasis that was successfully treated with a second administration of an EGFR-TKI. Magnetic resonance imaging showed spinal cord metastasis to the cervical vertebrae. The patient received a second administration of an EGFR-TKI (150 mg/day erlotinib). Four months later, we observed the disappearance of the paravertebral tumor and a reduction in the size of pulmonary tumors in both lungs. These results indicate that EGFR-TKI therapy could be a new strategy for the treatment of advanced lung adenocarcinoma with spinal metastasis.
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Fengtai District, Beijing, People's Republic of China.
Xiaoyan
X
Li
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Fengtai District, Beijing, People's Republic of China.
Hui
H
Yang
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Fengtai District, Beijing, People's Republic of China.
Jing
J
Zhao
Department of Lung Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Fengtai District, Beijing, People's Republic of China.
Hongjun
H
Gao
NSCLC; compression of spinal cord; erlotinib; target therapy